An in depth discussion about living with Hemophilia, HIV and Hepatitis C, Joe Burke opens up about living daily life with chronic illnesses, and where he gets inspiration from.
Monday, September 28, 2015
An In Depth Discussion with Joe Burke, Surviving Hemophilia, HIV and Hepatitis C
An in depth discussion about living with Hemophilia, HIV and Hepatitis C, Joe Burke opens up about living daily life with chronic illnesses, and where he gets inspiration from.
Tuesday, September 15, 2015
Webinar on Blab September 28th, 2015 - 1PM EST
Brett from Next Big Thing Radio, interviewed me last night about my upcoming #webinar on #Hemophilia, #HIV and #HepatitisC. I encourage you to watch this video and join me live on September 28th, 1PM Eastern. Subscribe ➼ https://blab.im/bqetva
Saturday, September 12, 2015
Live Educational Interactive Webinar on Blab September 28th, 2015 - 1PM EST
Join “#iStrive2Thrive” founder & advocate for #hemophilia, #HIV and#HepatitisC, Joseph Burke live on #Blab! WEB ADDRESS : http://BLAB.IM/BQETVA on September 28th, 2015 at 1PM Eastern. Ask the difficult questions in an all new innovative and interactive platform. Get an inside look into the life of living life with multiple chronic illnesses, and how face your giants head on.
Friday, September 11, 2015
Factoring Up Will Never Be The Same
Today September 11th, 2015 is a date in which we not only pause to reflect on the tragic events 14 years ago in New York City and the Nation's Capitol, but strangely enough, a day of rejoicing within the bleeding disorders community. The FDA announced today that Roche's new drug ACE910 has been escalated to fast track status promising amazing results and a game changer among hemophiliacs suffering with Type A severe clotting disorders.
The new drug will be a breakthrough "subcutaneous injection" steering away from the traditional vein or port access among hemophiliacs today. The under the skin injection will be administered once a week among hemophiliac patients who have no inhibitors to factor VIII proteins. The first trials are expected to commence in early 2016 in young pediatric patients with Type A severe hemophilia. Control studies will be tested in both inhibitor resistant and non-inhibitor patients.
"Sandra Hornung, the chief medical officer at Roche, said that the FDA granted permission because they recognize that it meets a segment of the population that it hasn’t met before." PPPFocus.com
As a hemophiliac myself, having my veins accessed for the past 35 years, this new anti-hemophiliac factor VIII will be one to keep our eyes on. Though the nation may mourn the events of 14 years, members of the bleeding disorder community rejoice today in light of Roche's announcement of the new hemophilia drug.
Full Article: http://www.pppfocus.com/hemophilia-drug-given-fda-fast-track-designation-303295/
The new drug will be a breakthrough "subcutaneous injection" steering away from the traditional vein or port access among hemophiliacs today. The under the skin injection will be administered once a week among hemophiliac patients who have no inhibitors to factor VIII proteins. The first trials are expected to commence in early 2016 in young pediatric patients with Type A severe hemophilia. Control studies will be tested in both inhibitor resistant and non-inhibitor patients.
"Sandra Hornung, the chief medical officer at Roche, said that the FDA granted permission because they recognize that it meets a segment of the population that it hasn’t met before." PPPFocus.com
As a hemophiliac myself, having my veins accessed for the past 35 years, this new anti-hemophiliac factor VIII will be one to keep our eyes on. Though the nation may mourn the events of 14 years, members of the bleeding disorder community rejoice today in light of Roche's announcement of the new hemophilia drug.
Full Article: http://www.pppfocus.com/hemophilia-drug-given-fda-fast-track-designation-303295/
Subscribe to:
Posts (Atom)